REGENXBIO, Inc.
(NASDAQ : RGNX)

( )
RGNX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.53%87.991.3%$894.47m
AMGNAmgen Inc.
0.04%191.311.2%$560.48m
ONCESpark Therapeutics, Inc.
0.33%113.9611.2%$458.43m
GILDGilead Sciences, Inc.
-0.93%65.020.9%$450.52m
BIIBBiogen Inc.
-1.28%325.651.3%$354.96m
BPTHBio-Path Holdings, Inc.
-5.48%27.79190.1%$296.94m
REGNRegeneron Pharmaceuticals, Inc.
-1.66%407.602.6%$280.72m
ILMNIllumina, Inc.
-1.31%305.783.5%$269.47m
VRTXVertex Pharmaceuticals Incorporated
-0.32%187.481.9%$245.27m
SRPTSarepta Therapeutics, Inc.
-1.20%126.8215.4%$210.77m
EXASExact Sciences Corporation
-3.44%91.9325.3%$194.56m
ALXNAlexion Pharmaceuticals, Inc.
-1.90%133.512.0%$181.24m
AAgilent Technologies, Inc.
-0.16%80.971.6%$153.74m
IONSIonis Pharmaceuticals, Inc.
1.25%79.528.3%$101.55m
BMRNBioMarin Pharmaceutical Inc.
-1.24%93.364.3%$97.41m

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.